1. Market Research
  2. > Light Sciences Oncology, Inc. – Product Pipeline Review – 2013

Light Sciences Oncology, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 28 pages

Light Sciences Oncology, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Light Sciences Oncology, Inc. - Product Pipeline Review - 2013” provides data on the Light Sciences Oncology, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Light Sciences Oncology, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Light Sciences Oncology, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Light Sciences Oncology, Inc. - Brief Light Sciences Oncology, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Light Sciences Oncology, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Light Sciences Oncology, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Light Sciences Oncology, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Light Sciences Oncology, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Light Sciences Oncology, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Light Sciences Oncology, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Light Sciences Oncology, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Light Sciences Oncology, Inc. and identify potential opportunities in those areas.

Table Of Contents

Light Sciences Oncology, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Light Sciences Oncology, Inc. Snapshot 4
Light Sciences Oncology, Inc. Overview 4
Key Information 4
Key Facts 4
Light Sciences Oncology, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Light Sciences Oncology, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Light Sciences Oncology, Inc. - Pipeline Products Glance 9
Light Sciences Oncology, Inc. - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
Light Sciences Oncology, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Light Sciences Oncology, Inc. - Drug Profiles 11
talaporfin sodium 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Light Sciences Oncology, Inc. - Pipeline Products by Route of Administration 14
Light Sciences Oncology, Inc. - Recent Pipeline Updates 15
Light Sciences Oncology, Inc. - Dormant Projects 16
Light Sciences Oncology, Inc. - Locations And Subsidiaries 17
Head Office 17
Light Sciences Oncology, Inc., Recent Developments 18
Light Sciences Oncology, Inc.- Press Release 18
Feb 26, 2010: Light Sciences Oncology Achieves Milestone In Clinical Development Of Aptocine 18
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 18
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 19
Financial Deals Landscape 20
Light Sciences Oncology, Inc., Deals Summary 20
Light Sciences Oncology, Inc., Pharmaceuticals and Healthcare, Deal Details 21
Venture Financing 21
Light Sciences Oncology Raises US$1.3 Million In Venture Financing 21
Light Sciences Oncology Raises US$1.26 Million In Venture Financing 22
Light Sciences Oncology Secures US$12 Million In Venture Financing 23
Light Sciences Oncology Secures US$40.1 Million In Series C Financing 24
Light Sciences Oncology Secures US$30 Million In Series B Preferred Stock Financing 25
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28



List of Tables

Light Sciences Oncology, Inc., Key Information 4
Light Sciences Oncology, Inc., Key Facts 4
Light Sciences Oncology, Inc. - Pipeline by Indication, 2013 6
Light Sciences Oncology, Inc. - Pipeline by Stage of Development, 2013 7
Light Sciences Oncology, Inc. - Monotherapy Products in Pipeline, 2013 8
Light Sciences Oncology, Inc. - Phase III, 2013 9
Light Sciences Oncology, Inc. - Phase II, 2013 10
Light Sciences Oncology, Inc. - Pipeline By Route of Administration, 2013 14
Light Sciences Oncology, Inc. - Recent Pipeline Updates, 2013 15
Light Sciences Oncology, Inc. - Dormant Developmental Projects,2013 16
Light Sciences Oncology, Inc., Deals Summary 20
Light Sciences Oncology Raises US$1.3 Million In Venture Financing 21
Light Sciences Oncology Raises US$1.26 Million In Venture Financing 22
Light Sciences Oncology Secures US$12 Million In Venture Financing 23
Light Sciences Oncology Secures US$40.1 Million In Series C Financing 24
Light Sciences Oncology Secures US$30 Million In Series B Preferred Stock Financing 25



List of Figures

Light Sciences Oncology, Inc. - Pipeline by Indication, 2013 6
Light Sciences Oncology, Inc. - Pipeline by Stage of Development, 2013 7
Light Sciences Oncology, Inc. - Monotherapy Products in Pipeline, 2013 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.